Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA

Published 2016 View Full Article

Authors

Keywords

cell-free circulating tumor DNA, KRAS, EGFR, activating mutation, tyrosine kinase inhibitors

Journal

Oncotarget

Volume 8, Issue 8, Pages -

Publisher

Impact Journals, LLC

Online

2016-01-20

DOI

10.18632/oncotarget.6957

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started